Journal of Pharmaceutical Research
DOI: 10.18579/jopcr/v18.4.vishal
Year: 2019, Volume: 18, Issue: 4, Pages: 12-16
Original Article
Vishal Malviya1, Manjunath Ghate1
1Department of Pharmaceutical Chemistry, Krupanidhi College of Pharmacy, Bangalore, 560035, Karnataka, India
Flupentixol, a potent antipsychotic and antidepressant, exists in two geometric isomers, Z and E, with the Z-isomer being the therapeutically active form. The synthesis of flupentixol and related compounds often faces the challenge of controlling the stereochemistry to favor the Z-isomer. The study aimed to identify the optimal conditions for producing the Z-isomer, which is more therapeutically relevant. 2-(trifluoromethyl)-9H-thioxanthen-9-one was prepared from 2-mercaptobenzoic acid and perabromobenzotrifluoride, followed by a Grignard rearrangement to form (9-(3-dimethylamino)propyl)-2-(trifluoromethyl)-9,10aH-dihydro-8aH-thioxanthen-9-ol. The intermediate was dehydrated with various acids to produce the E and Z isomers of Flupentixol, with the product ratios subsequently analyzed using ¹H-NMR spectroscopy. The dehydration reactions yielded different E/Z isomer ratios, yields, and melting points, depending on the acid used. Hydrochloric, oxalic, and methanesulfonic acids favored the formation of the Z-isomer with E/Z ratios of 11:89, 14:86, and 12:88, respectively, while succinic acid achieved the highest yield (84.75%) with a 37:63 E/Z ratio. Maleic acid and ferrous sulfate produced intermediate ratios, and DL- and L(+)-tartaric acids gave similar results with high yields. This study revealed a novel insight into the influence of various acids on the dehydration reactions, highlighting specific acids that significantly favor the formation of the therapeutically active Z-isomer of Flupentixol with optimized yields and ratios.
Keywords: Flupentixol, Zisomer, Eisomer, Antipsychotic drugs, ¹HNMR, Racemic resolution
© 2019 Published by Krupanidhi College of Pharmacy. This is an open-access article under the CC BY-NC-ND license (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Subscribe now for latest articles and news.